FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1556094624> ?p ?o ?g. }

• W1556094624 abstract "There are many molecular differences between estrogen receptor α (ERα)-positive and ER-negative breast cancers. Recent analyses have shown that the former can be divided into two subtypes, luminal A and luminal B. These differ in response to endocrine therapy and chemotherapy, and in prognosis. In a previous study, we found that microRNA (miR)-1290 that was significantly down-regulated in luminal A tumors and its potential target arylamine N-acetyltransferase 1 (NAT1). The aim of the present study was to determine whether NAT1 is a bona fide target of miR-1290, and to investigate the impact of NAT1 on breast cancer prognosis. Luciferase reporter assays were employed to validate NAT1 as a putative miR-1290 target gene. Expression of NAT1, ERα, progesterone receptor (PgR) and HER2 was analyzed in 394 breast cancer samples by immunohistochemistry. NAT1 was confirmed to be a direct target of miR-1290. Levels of expression of NAT1 were positively correlated with those of ERα (P < 0.0001) and PgR (P < 0.0001), but negatively correlated with both tumor grade and size (P < 0.0001). Kaplan-Meier analysis showed that the presence of NAT1 was significantly associated with increased overall survival (OS) (P = 0.0416) in these patients. Similarly, significant associations of NAT1 with disease-free survival (DFS) (P = 0.0048) and OS (P = 0.0055) in those patients who received adjuvant endocrine therapy with tamoxifen (n = 176) were found. Moreover, NAT1 was also significantly associated with increased DFS (P = 0.0025) and OS (P = 0.0007) in the subset of lymph node-positive patients (n = 147). Univariate and multivariate analyses showed significant associations between levels of NAT1 and DFS (P = 0.0005 and 0.019, respectively). We report that miR-1290 directly targets the NAT1 3′-UTR and that NAT1 protein expression is correlated with improved OS of breast cancer patients. NAT1 is a possible prognostic biomarker for lymph node-positive breast cancer. Thus, miR-1290 and its target NAT1 are associated with important characteristics of breast cancer." @default.
• W1556094624 created "2016-06-24" @default.
• W1556094624 creator A5004323435 @default.
• W1556094624 creator A5007636706 @default.
• W1556094624 creator A5009237974 @default.
• W1556094624 creator A5017280283 @default.
• W1556094624 creator A5027634537 @default.
• W1556094624 creator A5031327561 @default.
• W1556094624 creator A5037523844 @default.
• W1556094624 creator A5064588100 @default.
• W1556094624 creator A5074407662 @default.
• W1556094624 creator A5081433438 @default.
• W1556094624 date "2014-12-01" @default.
• W1556094624 modified "2023-10-15" @default.
• W1556094624 title "Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer" @default.
• W1556094624 cites W1648301895 @default.
• W1556094624 cites W1850156578 @default.
• W1556094624 cites W1952488157 @default.
• W1556094624 cites W1965296962 @default.
• W1556094624 cites W1974613169 @default.
• W1556094624 cites W1992316503 @default.
• W1556094624 cites W2018351534 @default.
• W1556094624 cites W2043203418 @default.
• W1556094624 cites W2044702943 @default.
• W1556094624 cites W2054125495 @default.
• W1556094624 cites W2059357290 @default.
• W1556094624 cites W2062592533 @default.
• W1556094624 cites W2065798047 @default.
• W1556094624 cites W2084578827 @default.
• W1556094624 cites W2088852867 @default.
• W1556094624 cites W2097255042 @default.
• W1556094624 cites W2104635744 @default.
• W1556094624 cites W2116097178 @default.
• W1556094624 cites W2121091450 @default.
• W1556094624 cites W2124007301 @default.
• W1556094624 cites W2130900820 @default.
• W1556094624 cites W2136197148 @default.
• W1556094624 cites W2137638337 @default.
• W1556094624 cites W2137983743 @default.
• W1556094624 cites W2140521765 @default.
• W1556094624 cites W2143915199 @default.
• W1556094624 cites W2157840751 @default.
• W1556094624 cites W2231000545 @default.
• W1556094624 cites W2259802687 @default.
• W1556094624 cites W3020903920 @default.
• W1556094624 cites W626666553 @default.
• W1556094624 doi "https://doi.org/10.1186/1471-2407-14-990" @default.
• W1556094624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4364092" @default.
• W1556094624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25528056" @default.
• W1556094624 hasPublicationYear "2014" @default.
• W1556094624 type Work @default.
• W1556094624 sameAs 1556094624 @default.
• W1556094624 citedByCount "46" @default.
• W1556094624 countsByYear W15560946242015 @default.
• W1556094624 countsByYear W15560946242016 @default.
• W1556094624 countsByYear W15560946242017 @default.
• W1556094624 countsByYear W15560946242018 @default.
• W1556094624 countsByYear W15560946242019 @default.
• W1556094624 countsByYear W15560946242020 @default.
• W1556094624 countsByYear W15560946242021 @default.
• W1556094624 countsByYear W15560946242022 @default.
• W1556094624 countsByYear W15560946242023 @default.
• W1556094624 crossrefType "journal-article" @default.
• W1556094624 hasAuthorship W1556094624A5004323435 @default.
• W1556094624 hasAuthorship W1556094624A5007636706 @default.
• W1556094624 hasAuthorship W1556094624A5009237974 @default.
• W1556094624 hasAuthorship W1556094624A5017280283 @default.
• W1556094624 hasAuthorship W1556094624A5027634537 @default.
• W1556094624 hasAuthorship W1556094624A5031327561 @default.
• W1556094624 hasAuthorship W1556094624A5037523844 @default.
• W1556094624 hasAuthorship W1556094624A5064588100 @default.
• W1556094624 hasAuthorship W1556094624A5074407662 @default.
• W1556094624 hasAuthorship W1556094624A5081433438 @default.
• W1556094624 hasBestOaLocation W15560946241 @default.
• W1556094624 hasConcept C121608353 @default.
• W1556094624 hasConcept C126322002 @default.
• W1556094624 hasConcept C143998085 @default.
• W1556094624 hasConcept C204232928 @default.
• W1556094624 hasConcept C2777176818 @default.
• W1556094624 hasConcept C2780140570 @default.
• W1556094624 hasConcept C2781197716 @default.
• W1556094624 hasConcept C2910080358 @default.
• W1556094624 hasConcept C502942594 @default.
• W1556094624 hasConcept C530470458 @default.
• W1556094624 hasConcept C55493867 @default.
• W1556094624 hasConcept C71924100 @default.
• W1556094624 hasConcept C84606932 @default.
• W1556094624 hasConcept C86803240 @default.
• W1556094624 hasConcept C98717036 @default.
• W1556094624 hasConceptScore W1556094624C121608353 @default.
• W1556094624 hasConceptScore W1556094624C126322002 @default.
• W1556094624 hasConceptScore W1556094624C143998085 @default.
• W1556094624 hasConceptScore W1556094624C204232928 @default.
• W1556094624 hasConceptScore W1556094624C2777176818 @default.
• W1556094624 hasConceptScore W1556094624C2780140570 @default.
• W1556094624 hasConceptScore W1556094624C2781197716 @default.
• W1556094624 hasConceptScore W1556094624C2910080358 @default.
• W1556094624 hasConceptScore W1556094624C502942594 @default.
• W1556094624 hasConceptScore W1556094624C530470458 @default.
• W1556094624 hasConceptScore W1556094624C55493867 @default.

• next